CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a nanomolar-potency, highly selective cathepsin B inhibitor that blocks a critical proteolytic cascade implicated in cancer metastasis, immune modulation, and neurotoxicity (Liu et al., 2024). Its inhibition constant (Ki) for cathepsin B is 2–5 nM, with >10,000-fold selectivity over cathepsins H and L. CA-074 has demonstrated efficacy in reducing breast cancer bone metastasis and suppressing neurotoxic responses in vitro and in vivo (APExBIO, A1926 kit). The compound exhibits low cytotoxicity in cell culture (≤10 mM) and offers robust solubility in DMSO, ethanol, and water. Recent studies highlight the centrality of cathepsin B in necroptosis and lysosomal membrane permeabilization, positioning CA-074 as an essential tool for mechanistic studies (DOI).

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in protein degradation and cellular homeostasis. Dysregulation of cathepsin B activity is implicated in cancer cell invasion, metastasis, neurodegeneration, and immune response modulation (Liu et al., 2024). During necroptosis, lysosomal membrane permeabilization (LMP) leads to the release of cathepsin B, which in turn cleaves essential cellular proteins, promoting cell death. Consequently, selective inhibition of cathepsin B is a powerful strategy for dissecting protease-mediated disease mechanisms and for modulating pathological processes such as cancer metastasis and neuroinflammation (see overview).

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a small molecule inhibitor that covalently binds to the active site of cathepsin B, irreversibly blocking its proteolytic activity. The compound exhibits an inhibition constant (Ki) of 2–5 nM for cathepsin B, reflecting high affinity under physiological pH and ionic strength. CA-074 displays remarkable selectivity: for cathepsin H and L, the Ki values are 40–200 µM, indicating >10,000-fold preference for cathepsin B (APExBIO). This specificity enables targeted inhibition of cathepsin B-mediated proteolytic cascades while minimizing off-target effects. Mechanistically, CA-074 prevents cathepsin B from degrading extracellular matrix components, attenuates pro-metastatic signaling, and disrupts neurotoxic cascades initiated by microglial activation (extension of prior work).

Evidence & Benchmarks

• CA-074 inhibits cathepsin B with a Ki of 2–5 nM, providing >10,000-fold selectivity over cathepsins H and L (APExBIO, product datasheet).
• In a 4T1.2 breast cancer mouse model, intraperitoneal injection of CA-074 (50 mg/kg) reduced bone metastases without affecting primary tumor size (APExBIO, A1926 kit).
• CA-074 shifts immune response from Th-2 to Th-1, reducing IgE and IgG1 production in vivo (Liu et al., 2024).
• CA-074 suppresses neurotoxic effects induced by Abeta42-activated microglial cells, supporting its use in neurotoxicity models (updated mechanistic insights).
• Chemical inhibition of cathepsin B with CA-074 protects cells from MLKL polymerization-induced necroptosis (Liu et al., 2024).
• CA-074 is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonic assistance) (APExBIO).
• In cell culture, CA-074 shows negligible cytotoxicity at concentrations up to 10 mM (APExBIO).

Applications, Limits & Misconceptions

CA-074's high selectivity and potency make it a preferred tool for:

• Studying cathepsin B's role in tumor metastasis and the extracellular matrix degradation process.
• Dissecting immune regulation, especially Th-2 to Th-1 helper T cell switching and antibody subclass modulation (provides extended application context).
• Modeling neurotoxicity pathways involving microglial activation and Abeta42-induced responses.
• Elucidating the molecular events of necroptosis, particularly MLKL-driven lysosomal membrane permeabilization (primary DOI).

Common Pitfalls or Misconceptions

• Non-selectivity at high concentrations: At supramaximal concentrations, minor off-target inhibition of related cathepsins may occur; optimal dosing is critical for specificity.
• Incompatibility with chronic dosing in vivo: Long-term systemic use can lead to lysosomal dysfunction; CA-074 is best suited for acute or mechanistic studies.
• Ineffectiveness against non-cysteine proteases: CA-074 does not inhibit aspartic or serine proteases (e.g., cathepsin D or trypsin) and should not be used for broad-spectrum protease inhibition.
• Solubility limitations in aqueous buffers without ultrasonic assistance: Water solubility is moderate and may require sonication for full dissolution.
• Not a therapeutic agent: CA-074 is a research tool, not approved for clinical use or therapeutic intervention.

Workflow Integration & Parameters

To achieve optimal results with CA-074 (SKU: A1926, APExBIO), researchers should consider the following workflow parameters:

• Preparation: Dissolve CA-074 in DMSO at ≥19.17 mg/mL, or in ethanol or water as needed; use ultrasonic assistance for water solubility.
• Storage: Store solid CA-074 at -20°C; prepare working solutions fresh, using within short timeframes to avoid degradation.
• In vitro dosing: Effective concentrations range from 10 nM to 10 μM; cytotoxicity is negligible up to 10 mM.
• In vivo dosing: Typical efficacy demonstrated at 50 mg/kg via intraperitoneal injection in mouse models of metastasis (A1926 kit).
• Controls: Include vehicle (e.g., DMSO) and non-inhibitor controls to verify specificity.

For advanced protocols and troubleshooting, see this mechanistic update, which details applications in LMP and immune modulation not fully covered here.

Conclusion & Outlook

CA-074, supplied by APExBIO, is a gold-standard research tool for selective inhibition of cathepsin B in oncology, immunology, and neurobiology. Its nanomolar potency, high selectivity, and robust solubility profile support a wide array of cell-based and in vivo applications. Recent mechanistic advances, especially in necroptosis and lysosomal biology, underscore the importance of precise cathepsin B inhibition in translational research (Liu et al., 2024). For researchers requiring validated, specific tools to dissect cathepsin B-mediated disease pathways, CA-074, Cathepsin B inhibitor remains unmatched in performance and reliability.